Testosterone Replacement Therapy (TRT)

Testosterone cypionate / enanthate / gel

TRT replaces testosterone in men with diagnosed hypogonadism. It can restore energy, libido, mood, and body composition — but it is a lifelong medical commitment with real trade-offs: fertility suppression, hematocrit shifts, and a small cardiovascular signal.

Androgen / anabolic steroid (bioidentical)Prescription requiredEvidence A
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.

Why it matters

Testosterone declines roughly 1% per year after age 30, but most age-related decline does not meet the threshold for medical hypogonadism. True deficiency — total testosterone below 264 ng/dL on two morning samples plus symptoms — affects roughly 2–6% of middle-aged men. For those men, TRT is genuinely life-changing: the T-Trials (Snyder et al., NEJM 2016) showed clinically meaningful improvements in sexual function, mood, walking distance, and anemia. Body composition improves modestly (lean mass up, fat mass down) and bone density rises. But TRT is not a youth elixir. The 2023 TRAVERSE trial settled the cardiovascular question for now: no significant increase in MACE versus placebo, though a small bump in atrial fibrillation and pulmonary embolism appeared. Fertility suppression is near-universal and not always reversible. Erythrocytosis is the most common dose-limiting issue. The honest framing: TRT is a powerful tool for diagnosed deficiency, not a performance shortcut for the low-normal range.

Uses

Label uses (approved)
  • Primary hypogonadism (testicular failure)
  • Secondary hypogonadism (hypothalamic/pituitary)
  • Klinefelter syndrome
  • Delayed puberty (select cases)

Dosing

Label dose
100–200 mg IM/SC cypionate every 7 days, OR 50–100 mg topical gel daily
Off-label / biohacker dose
Often divided to twice-weekly (e.g., 60–80 mg SC twice weekly) to flatten peaks/troughs
Titration: Start low (100 mg/week), recheck trough total T at week 6–8, target mid-normal (500–700 ng/dL). Estradiol, hematocrit, and symptoms guide dose — never chase supraphysiologic levels.
When to take: Same time of day for consistency; injectables typically morning; gels morning post-shower

Side effects & warnings

Common
  • Acne
  • Increased hematocrit / polycythemia
  • Testicular atrophy
  • Reduced fertility
  • Fluid retention
  • Mood changes
  • Sleep apnea worsening
Uncommon but serious
  • Gynecomastia (via aromatization)
  • Hair loss acceleration (in DHT-sensitive men)
  • Injection-site reactions
  • Skin transfer (topical)
Serious warnings
Erythrocytosis (Hct >54%) requires dose reduction or therapeutic phlebotomy. Worsens untreated obstructive sleep apnea. Contraindicated in active prostate or breast cancer. The 2023 TRAVERSE trial (NEJM, Lincoff et al.) found NO significant increase in major adverse cardiovascular events vs placebo in middle-aged/older men with hypogonadism, but did show a small increase in atrial fibrillation, pulmonary embolism, and acute kidney injury.

Biomarkers affected

apob
variable
Generally neutral; some studies show modest reduction, others no change.
Evidence: weak
estradiol
increase
Aromatization of exogenous testosterone routinely raises serum estradiol.
Evidence: strong
free testosterone
increase
Free T rises in parallel with total T, often disproportionately due to SHBG suppression.
Evidence: strong
hdl c
decrease
Modest HDL reduction common, particularly at higher doses; LDL/ApoB less consistent.
Evidence: moderate
hscrp
variable
Mixed data; some men show reduced inflammation, others no change.
Evidence: weak
lp a
decrease
Multiple studies and a meta-analysis report TRT lowers Lp(a) modestly (10–25%).
Evidence: moderate
shbg
decrease
Exogenous androgens suppress hepatic SHBG production.
Evidence: strong
total testosterone
increase
Direct serum testosterone replacement; targets mid-normal range (500–700 ng/dL).
Evidence: strong

Monitoring

Baseline: total T (two morning samples), free T, SHBG, LH, FSH, estradiol, hematocrit, PSA (>40y), lipid panel. Recheck at 3 months, 6 months, then annually.

The honest risk picture

## Realistic risks of TRT **Fertility:** TRT suppresses spermatogenesis in over 90% of users within months. Some men do not recover fertility even after discontinuation. If fertility is a current or future priority, discuss HCG co-administration or alternatives (clomiphene, enclomiphene) with a urologist BEFORE starting. **Erythrocytosis:** Roughly 6–25% of TRT users develop hematocrit above 52%. Above 54%, the risk of thrombotic events climbs and most clinicians require therapeutic phlebotomy or dose reduction. **Cardiovascular:** TRAVERSE (NEJM 2023, n≈5,200) found no significant increase in MACE. It DID find small absolute increases in atrial fibrillation (3.5% vs 2.4%), pulmonary embolism, and acute kidney injury. Men with uncontrolled heart failure or recent MI should not start TRT. **Prostate:** TRT does not appear to cause prostate cancer, but it can accelerate growth of pre-existing cancer. PSA monitoring is mandatory in men over 40. **Sleep apnea:** Pre-existing untreated OSA can worsen on TRT. Screen and treat first. **Mood/aggression:** Real for some men, but supraphysiologic doses are the main driver. Stay in mid-normal range. **Lifetime commitment:** Endogenous production rarely fully recovers after extended TRT. Treat this as a permanent intervention.

Practical context

Cost (US, retail)
$120/mo
Legality
Schedule III controlled substance in the US (Controlled Substances Act). Requires prescription. Telehealth TRT clinics legal but vary by state.
Interactions
true

FAQ

Does TRT shrink the testicles?+
Yes — exogenous testosterone suppresses LH, which is what tells the testicles to produce testosterone and sperm. Testicular volume typically decreases within months. HCG can be co-administered to preserve volume and fertility.
Is TRT for life?+
Usually yes. Once endogenous production is suppressed, stopping TRT means a return to baseline (or temporarily lower) testosterone. A formal PCT protocol can be attempted but recovery is not guaranteed, especially after years of use.
Does TRT cause heart attacks?+
The 2023 TRAVERSE trial — the largest RCT on TRT cardiovascular safety to date — found no significant increase in major adverse cardiac events versus placebo, though it did flag a small increase in atrial fibrillation and pulmonary embolism.
Can I start TRT if my testosterone is 'low-normal'?+
Endocrine Society guidelines recommend treatment only for unequivocally low total testosterone (<264 ng/dL on two morning samples) PLUS consistent symptoms. Treating low-normal levels is off-label and controversial.
References (5)+
  1. Endocrine Society Clinical Practice Guideline 2018 (Bhasin et al.).
  2. TRAVERSE trial — Cardiovascular Safety of Testosterone (Lincoff et al., NEJM 2023).
  3. Testosterone Trials in Older Men (Snyder et al., NEJM 2016).
  4. Effects of Testosterone on Lipoprotein(a) — meta-analysis.
  5. AUA Guideline on Evaluation and Management of Testosterone Deficiency (2018).
The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.

No spam. Unsubscribe anytime.